首页> 美国卫生研究院文献>PLoS Clinical Trials >Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada
【2h】

Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada

机译:加拿大不列颠哥伦比亚省艾滋病毒耐药性与获得耐药性检测的社会人口统计学相关性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Sociodemographic correlates of engagement in human immunodeficiency virus (HIV) care are well studied, however the association with accessing drug resistance testing (DRT) and the development of drug resistance have not been characterized. Between 1996–2014, 11 801 HIV patients accessing therapy in British Columbia were observed longitudinally. A subset of 9456 patients had testable viral load; of these 8398 were linked to census data. Sociodemographic (census tract-level) and clinical (individual-level) correlates of DRT were assessed using multivariable General Estimating Equation logistic regression adjusted odds ratios (aOR). The mean number of tests per patient was 2.1 (Q1-Q3; 0–3). Separately, any drug resistance was determined using IAS-USA (2013) list for 5703 initially treatment naïve patients without baseline resistance; 5175 were census-linked (mean of 1.5 protease-reverse transcriptase sequences/patient, Q1-Q3; 0–2). Correlates of detecting drug resistance in this subset were analyzed using Cox PH regression adjusted hazard ratios (aHR). Our results indicate baseline CD4 <200 cells/μL (aOR: 1.5, 1.3–1.6), nRTI-only baseline regimens (aOR: 1.4, 1.3–1.6), and unknown (therapy initiation before routine pVL in BC) baseline pVL (aOR: 1.8, 1.5–2.1) were among individual-level clinical covariates strongly associated with having accessed DRT; while imperfect adherence (aHR: 2.2, 1.9–2.5), low baseline CD4 count (aHR: 1.9, 1.6–2.3), and high baseline pVL (aHR: 2.0, 1.6–2.6) were associated with a higher likelihood of developing drug resistance. A higher median income (aOR: 0.83, 0.77–0.89) and higher percentage of those with aboriginal ancestry (aOR: 0.85, 0.76–0.95) were census tract-level sociodemographic covariates associated with decreased access to DRT. Similarly, aboriginal ancestry (aHR: 1.2, 1.1–1.5) was associated with development of drug resistance. In conclusion, clinical covariates continue to be the strongest correlates of development of drug resistance and access to DRT for individuals. Regions of high median income and high aboriginal ancestry were weak census-level sociodemographic indicators of reduced DRT uptake, however high aboriginal ancestry was the only sociodemographic indicator for development of drug resistance.
机译:参与人类免疫缺陷病毒(HIV)护理的社会人口统计学相关性已得到很好的研究,但是与获得抗药性测试(DRT)的相关性和抗药性的发展尚未得到表征。在1996年至2014年期间,纵向观察了不列颠哥伦比亚省的11 801名接受治疗的HIV患者。 9456名患者中有一部分可测病毒载量;在这8398个样本中,有一些与人口普查数据有关。 DRT的社会人口统计学(人口普查水平)和临床(个人水平)相关性使用多变量一般估计方程对数回归调整的优势比(aOR)进行评估。每位患者的平均测试数量为2.1(Q1-Q3; 0-3)。另外,使用IAS-USA(2013)清单确定了5703名没有基线耐药的初始治疗初治患者的任何耐药性; 5175个人口普查相关联(平均1.5个蛋白酶逆转录酶序列/患者,Q1-Q3; 0–2)。使用Cox PH回归调整后的危险比(aHR)分析了该子集中检测耐药性的相关性。我们的结果表明基线CD4 <200细胞/μL(aOR:1.5,1.3–1.6),仅nRTI基线方案(aOR:1.4,1.3–1.6)和未知(BC常规pVL之前的治疗开始)基线pVL(aOR :1.8,1.5–2.1)是与接受DRT密切相关的个体水平临床协变量之一;依从性不佳(aHR:2.2、1.9–2.5),基线CD4计数低(aHR:1.9、1.6–2.3)和基线pVL高(aHR:2.0、1.6–2.6)与产生耐药性的可能性更高。收入中位数较高(aOR:0.83,0.77–0.89)和原住民血统的比例较高(aOR:0.85,0.76–0.95)是与获得DRT减少相关的人口普查级社会人口统计学协变量。同样,原住民血统(aHR:1.2,1.1–1.5)与耐药性的发展有关。总之,临床协变量仍然是个体耐药性发展和获得DRT的最强相关因素。高中位数收入和高原住民血统的地区是减少DRT摄取的普查级社会人口统计学指标,但是高原住民血统是发展耐药性的唯一社会人口统计学指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号